Online mood booster tested for schizophrenia motivation
NCT ID NCT07157293
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a 12-week online program designed to improve mood and motivation in people with schizophrenia or early psychosis. Participants complete 20-30 minute weekly sessions. Researchers will measure changes in symptoms and goal-directed behavior before and after the program.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Online motivation-enhancing intervention
- What this could lead to
- If it works, this could offer a simple, accessible way to improve motivation and mood for people with schizophrenia.
- What could go wrong
- This is a small, early-stage trial with no control group, so results may not be conclusive. The intervention is online and self-directed, so engagement may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of schizophrenia or a related psychotic disorder * Meeting criteria for being at clinical high risk for psychosis Exclusion Criteria: * Does not have access to a computer each week
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psychosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35223-1517, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists build a computer model of the brain to explain hearing voices
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug